17
Participants
Start Date
November 30, 2015
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
PDX drug sensitivity testing
Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
Mount Sinai Hospital, Toronto
Lead Sponsor
Mount Sinai Hospital, Canada
OTHER
Champions Oncology
INDUSTRY